PT  - JOURNAL ARTICLE
AU  - Navarro, Marta de la Rubia
AU  - García, Elena Grau
AU  - Monreal, Ma Jesús Cuellar
AU  - Álvarez, Iago Alcántara
AU  - Verdejo, Inmaculada Chalmeta
AU  - Charia, Hikmat
AU  - Puig, Luis González
AU  - Huaylla Quispe, Anderson Víctor
AU  - Cortés, José Ivorra
AU  - Leal, Samuel
AU  - Cordellat, Isabel Martínez
AU  - Sánchez, Laura Mas
AU  - Muñoz Martínez, Pablo Francisco
AU  - Albuixech, Rosa Negueroles
AU  - Oller Rodríguez, José Eloy
AU  - Castro, Daniel Ramos
AU  - Bárcena, Carmen Riesco
AU  - Novés, Alba Torrat
AU  - Sugrañes, Ernesto Tovar
AU  - Bernabeu, Elvira Vicens
AU  - Mañes, Belén Villanueva
AU  - Olmos, Inés Cánovas
AU  - Herranz, Carmen Nájera
AU  - Román Ivorra, José Andrés
TI  - P149 Clinical worsening in non-adherent belimumab treatment in SLE
AID  - 10.1136/lupus-2024-el.203
DP  - 2024 Mar 01
TA  - Lupus Science & Medicine
PG  - A155--A156
VI  - 11
IP  - Suppl 1
4099  - http://lupus.bmj.com/content/11/Suppl_1/A155.2.short
4100  - http://lupus.bmj.com/content/11/Suppl_1/A155.2.full
SO  - Lupus Sci Med2024 Mar 01; 11
AB  - Objective The objective is to analyze the association between therapeutic adherence and disease activity in SLE patients.Methods An observational, prospective study in SLE patients (SLICC/ACR criteria), treated whit subcutaneous Belimumab (200 mg/week) was made. Disease activity was measured by SLEDAI in three consecutive visits, and it was considered clinical worsening an increase of SLEDAI-score of ≥4 point. Persistence and adherence of Belimumab data during the follow-up were collected and were calculated based on the number of drug dispensing. Poor therapeutic adherence was established under the 95%.Results Thirty-one prescriptions of Belimumab were registered (83.9% women) with a mean age of 48.1 (14.9) years. Time since the diagnosis was 12.5 (6.29) years and treatment period were 2.2 (1.4) years. Fifteen patients were considered as non-adherent (48.4%).Persistence and disease activity data in each group were showed in the table 1.View this table:Abstract P149 Table 1 Poor adherence was secondary to clinical improvement (66.67%), recurrent infections (13.33%), surgery (6.67%), pregnancy (6.67%) and inability to drug collect due to COVID-19 pandemic (6.67%). Non-adherent group showed worse SLEDAI-score than adherent group in V0, despite of a similar SLEDAI-score at V2 in both groups was observed. There was an association between poor therapeutic adherence and high delta_SLEDAI (p=0.046).Conclusions We observed an association between poor therapeutic adherence and delta_SLEDAI. The high SLEDAI-score at the beginning of the study in non-adherent group would be due to clinical manifestations, despite of the similar serological activity in both groups.